SCM
CAPR icon

Superstring Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Superstring Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-96,334
Closed -$2.78M – 39
2025
Q4 		$2.78M Buy
+96,334
New +$1.26M 1.49% 23
2025
Q2 		– Sell
-241,192
Closed -$2.29M – 37
2025
Q1 		$2.29M Buy
241,192
+185,963
+337% +$2.58M 2.72% 15
2024
Q4 		$762K Sell
55,229
-282,118
-84% -$4.94M 0.66% 29
2024
Q3 		$5.13M Buy
+337,347
New +$1.67M 4.49% 10

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Superstring Capital Management's CAPR Position: Q1 2026 in Review

Superstring Capital Management sold out of Capricor Therapeutics (CAPR) in Q1 2026, closing a stake of 96,334 shares — an estimated $2.78M sold.

Superstring Capital Management first reported a position in CAPR in Q3 2024 and held it in 4 quarters. The position peaked at $5.13M in Q3 2024. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Superstring Capital Management reported no remaining Capricor Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Superstring Capital Management sold 96,334 Capricor Therapeutics shares in Q1 2026, an estimated $2.78M.
  • Superstring Capital Management first reported a position in Capricor Therapeutics in Q3 2024 and held it in 4 quarters.
  • Superstring Capital Management's Capricor Therapeutics position peaked at $5.13M in Q3 2024.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.